SCHEMBL3524890

SCHEMBL3524890

O=C(O)c1cc(Cl)cc(Cl)c1Br

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 1/20 0.63
AKR1C3 P42330 1/20 0.63
AKR1C2 P52895 1/20 0.63
AKR1C1 Q04828 1/20 0.63
ALDH1A1 P00352 4/20 0.54
CASP1 P29466 2/20 0.54
TP53 P04637 1/20 0.54
TSHR P16473 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HPGD P15428 3/20 0.52
HSD17B10 Q99714 2/20 0.52
CYP3A4 P08684 1/20 0.50
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
POLB P06746 2/20 0.44
TPMT P51580 1/20 0.44
USP2 O75604 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30863904 0.83 AKR1C2 (0.48) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL11679297 0.83 TTR (0.54) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL8152700 0.81 AKR1C4 (0.68) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL27980487 0.81 ALDH1A1 (0.44) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL24157724 0.81 TDP1 (0.46) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL31233641 0.80 AKR1C3 (0.55) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL1614866 0.79 AKR1C4 (0.65) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL1812602 0.78 ALDH1A1 (0.48) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL23529333 0.78 ALDH1A1 (0.48) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL28406215 0.78 ABL1 (0.46) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061767-B1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use SANOFI SA (FR) 2014-12-17 EP disclosed
US-7759366-B2 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2010-07-20 US disclosed
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use SANOFI-AVENTIS (FR) 2009-08-27 US disclosed
EP-2061767-A1 ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE Sanofi-Aventis (FR) 2009-05-27 EP disclosed
WO-2008017381-A1 ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE SANOFI-AVENTIS (FR) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215728-A1 Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use GPR119, GIPR, LIPC AKR1C4 510/4885AKR1C3 417/4885AKR1C2 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.